Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

EVP, Head of Omnichannel & Digital Transformation with EVERSANA INTOUCH.

Articles

Pharma must align data, personalization, and cross-functional orchestration to deliver human-centered experiences that connect with patients, HCPs, and caregivers alike.

Omnichannel, Evolved: Redefining the Model for Modern Pharma Marketing

. He can be reached at nsaraceno@mjhlifesciences.com.

Podcasts

This episode of Pharma Pulse dives into Cardinal Health’s acquisition of Solaris Health to strengthen specialty services, how hospital networks are investing in centralized pharmacy hubs to improve efficiency and supply chain resilience, and new research linking GLP-1 drugs to potential optic nerve disorders.

Pharma Pulse: Cardinal Health Expands with Solaris Acquisition, Hospitals Centralize Pharmacy Hubs, and GLP-1 Safety Signals Emerge

Videos

In the first part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, explains how steep pharmaceutical import tariffs might affect costs at different points in the supply chain, why component pricing poses a bigger risk than active ingredients, and how insurers, distributors, and manufacturers may negotiate to shield patients from price increases.

Potential 250% Pharma Tariffs Could Pressure Margins Without Directly Raising Patient Costs

Senior Vice President, Market Development, at ConnectiveRx.

Conversation with chief tech expert explores AI’s rise in the support 
space—and separating the substance from the noise. 

Questions Patient Access Leaders Should Be Asking About AI (But Aren’t)

Health systems across the United States are opening large-scale pharmacy service centers to streamline operations, improve inventory control, and ensure timely medication delivery amid drug shortages and rising costs.

Hospital Networks Invest in Centralized Pharmacy Hubs to Cut Costs and Strengthen Supply Chains

Founder and Principal Consultant at 1st Line Partners.

Counterfeit drugs infiltrating the US pharma supply chain through gray market channels underscore the urgent need for vigilance.

Caveat Emptor in the Gray Market

This episode of Pharma Pulse covers Vinay Prasad’s return to lead the FDA’s biologics center after a brief resignation, new research on severe COVID-19 risks for childhood cancer survivors, and the strategies pharma companies are adopting to stay competitive amid escalating healthcare costs.

Pharma Pulse: Vinay Prasad Reinstated as FDA CBER Head, New COVID-19 Risk Data, and the Industry’s Response to Rising Costs

Why it’s time to act on passing key bills to boost access for millions.


Insurance Barriers Delaying Patient Care

In the final part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, discusses operational and pricing strategies pharma executives can adopt to navigate sustained cost inflation, including supply chain optimization, payer collaboration, and value-based approaches to ensure patient access and affordability.

How Pharma Can Remain Competitive Amid Rising Healthcare Costs

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.


Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs